MedTrace Logo

Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen in Norway: A Validation Study

NCT03579017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2024-10-30

No results posted yet for this study

Summary

Cognitive impairment is present in about 30-50% of the patients with amyotrophic lateral sclerosis (ALS). Suitable screening tools are available, but none of these are evaluated in a Norwegian population.

Conditions

Interventions

DIAGNOSTIC_TEST

ECAS-N

All participants included will be tested with the ECAS-N

DIAGNOSTIC_TEST

MoCA

All included patients With ALS will be tested With the MoCA

Sponsors & Collaborators

  • Western Norway University of Applied Sciences

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Tina Taule, PhD · Haukeland University Hospital

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2022-12-31
Completion
2023-05-04

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03579017 on ClinicalTrials.gov